Vizsgálati helyszín
Specialized Hospital For Active Treatment Of Hematological Diseases EAD
Sofiya, 1797, BulgáriaEU-13 felzárkózó országMég nincs intézményhez kötve
- 22futó vizsgálat
- 6lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 28 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis17 vizsgálat
- 1. fázis4 vizsgálat
- 2. fázis3 vizsgálat
- 4. fázis2 vizsgálat
- 1/2. fázis1 vizsgálat
- 2/3. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz12 vizsgálat
- Toboroz9 vizsgálat
- Lezárult6 vizsgálat
- Még nem toboroz1 vizsgálat
- Fő szponzor
- Ascentage Pharma Group Inc.4 vizsgálat
- Takeda3 vizsgálat
- Novartis Pharmaceuticals2 vizsgálat
- BeOne Medicines1 vizsgálat
- Celgene Corp.1 vizsgálat
- és még 17
Futó vizsgálatok
Toboroz
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· 3. fázis· Takeda· Forrás
Toboroz
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
NCT07422480· 3. fázis· Takeda· Forrás
Fut, nem toboroz
A study to find how well budoprutug (TNT119) works and how safe it is in participants with immune thrombocytopenia
2024-519745-30-01· 1/2. fázis· Climb Bio Inc.· Forrás
Toboroz
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285· 3. fázis· Takeda· Forrás
Toboroz
Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
2024-511346-39-00· 1. fázis· Chugai Pharmaceutical Co. Ltd.· Forrás
Fut, nem toboroz
Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa
NCT06716814· 3. fázis· Swedish Orphan Biovitrum· Forrás
Toboroz
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
NCT06641414· 3. fázis· Ascentage Pharma Group Inc.· Forrás
Toboroz
A Phase Ib Safety, Pharmacokinetics and Pharmacodynamics Study of TU7710 in Patients with Haemophilia A or B
2024-511814-20-00· 1. fázis· Tiumbio Co. Ltd.· Forrás
Fut, nem toboroz
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417· 1. fázis· Chugai Pharmaceutical· Forrás
Toboroz
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects
with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
2024-511309-47-00· 2. fázis· Karyopharm Therapeutics Inc.· Forrás
Fut, nem toboroz
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744· 3. fázis· Genmab· Forrás
Toboroz
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
NCT06003387· 3. fázis· CSL Behring· Forrás
Toboroz
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566· 3. fázis· Ascentage Pharma Group Inc.· Forrás
Toboroz
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
NCT05645107· 3. fázis· Grifols Therapeutics LLC· Forrás
Fut, nem toboroz
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
NCT05429268· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Asciminib Roll-over Study
NCT04877522· 4. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862· 3. fázis· BeOne Medicines· Forrás
Fut, nem toboroz
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980· 3. fázis· Loxo Oncology, Inc.· Forrás
Fut, nem toboroz
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)
NCT03662126· 2/3. fázis· Kartos Therapeutics Inc.· Forrás
Fut, nem toboroz
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113· 2. fázis· GlaxoSmithKline· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek